Temporal characteristics of botulinum neurotoxin therapy

References

• Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat. Disord.13(Suppl. 3), S362–S368 (2007).
   PubMed Web of Science ®Google Scholar
• Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol.44, 167–193 (2004).
   PubMed Web of Science ®Google Scholar
• Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev.80, 717–766 (2000).
   PubMed Web of Science ®Google Scholar
• Morbiato L, Carli L, Johnson EA, Montecucco C, Molgo J, Rossetto O. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C. Eur. J. Neurosci.25, 2697–2704 (2007).
   PubMedGoogle Scholar
• Lawrence G, Wang J, Chion CK, Aoki KR, Dolly JO. Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E. J. Pharmacol. Exp. Ther.320, 410–418 (2007).
   PubMedGoogle Scholar
• Lebeda FJ, Adler M, Erickson K, Chushak Y. Onset dynamics of type A botulinum neurotoxin-induced paralysis. J. Pharmacokinet. Pharmacodyn.35, 251–267 (2008).
   PubMedGoogle Scholar
• Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther.212, 16–21 (1980).
   PubMed Web of Science ®Google Scholar
• Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord.19(Suppl. 8), S129–S136 (2004).
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology70, 1707–1714 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Blitzer A, Brashear A et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology70, 1699–1706 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Graham HK et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology70, 1691–1698 (2008).
   PubMed Web of Science ®Google Scholar
• Mudunuri U, Stephens R, Bruining D, Liu D, Lebeda FJ. BotXminer: mining biomedical literature with a new web-based application. Nucleic Acids Res.34, W748–W752 (2006).
   Google Scholar
• Hines HB, Lebeda F, Hale M, Brueggemann EE. Characterization of botulinum progenitor toxins by mass spectrometry. Appl. Environ. Microbiol.71, 4478–4486 (2005).
   PubMedGoogle Scholar
• Barr JR, Moura H, Boyer AE et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg. Infect. Dis.11, 1578–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs62, 705–722 (2002).
   PubMedGoogle Scholar
• Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol. Clin.26(Suppl. 1), 43–53 (2008).
   PubMedGoogle Scholar
• Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur. J. Neurol.13(Suppl. 1), 11–15 (2006).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett.13, 1–4 (2008).
   PubMedGoogle Scholar
• Hunt T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J. Am. Acad. Dermatol.58, 517–518 (2008).
   PubMedGoogle Scholar
• Taban M, Perry JD. Pearls of botox usage. Oculoplastic Surgery4, 165–169 (2006).
   Google Scholar
• Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J. R. Soc. Med.86, 493–494 (1993).
   PubMed Web of Science ®Google Scholar
• Niemann H. Clostridial neurotoxins – proposal of a common nomenclature. Toxicon30, 223–225 (1992).
   PubMedGoogle Scholar
• Lebeda FJ. BotDB: a database resource for the clostridial neurotoxins. Mov. Disord.19(Suppl. 8), S35–S41 (2004).
   Google Scholar
• Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res.37, W441–W445 (2009).
   Web of Science ®Google Scholar
• Lim EC, Seet RC. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol. Scand.117, 73–84 (2008).
   PubMed Web of Science ®Google Scholar
• Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural Transm.112, 905–913 (2005).
   PubMed Web of Science ®Google Scholar
• Kranz G, Haubenberger D, Voller B et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov. Disord.24, 231–236 (2009).
   PubMed Web of Science ®Google Scholar
• Arndt JW, Gu J, Jaroszewski L et al. The structure of the neurotoxin-associated protein HA33/A from Clostridium botulinum suggests a reoccurring β-trefoil fold in the progenitor toxin complex. J. Mol. Biol.346, 1083–1093 (2005).
   PubMedGoogle Scholar
• Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev. Neurother.7(6), 637–647 (2007).
   PubMedGoogle Scholar
• Moy R, Maas C, Monheit G, Huber MB. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch. Facial Plast. Surg.11, 77–83 (2009).
   PubMedGoogle Scholar
• Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov. Disord.20, 592–597 (2005).
   PubMed Web of Science ®Google Scholar
• Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J. Neural. Transm.116, 437–441 (2009).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov. Disord.11, 250–256 (1996).
   PubMed Web of Science ®Google Scholar
• Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol. Surg.29, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Sadick NS, Faacs. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol. Surg.28, 817–821 (2002).
   PubMedGoogle Scholar
• Comella CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology65, 1423–1429 (2005).
   PubMed Web of Science ®Google Scholar
• Aoki KR. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon40, 923–928 (2002).
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science312, 592–596 (2006).
   PubMed Web of Science ®Google Scholar
• Chen R, Karp BI, Goldstein SR, Bara-Jimenez W, Yaseen Z, Hallett M. Effect of muscle activity immediately after botulinum toxin injection for writer’s cramp. Mov. Disord.14, 307–312 (1999).
   PubMed Web of Science ®Google Scholar
• Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur. Neurol.53, 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Chancellor MB. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int. Urol. Nephrol. DOI: 10.1007/s11255-009-9600-7 (2009) (Epub ahead of print).
   Google Scholar
• Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci. Lett.224, 91–94 (1997).
   PubMed Web of Science ®Google Scholar
• Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur. J. Neurol.13(Suppl. 4), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Washbourne P, Pellizzari R, Rossetto O et al. On the action of botulinum neurotoxins A and E at cholinergic terminals. J. Physiol. Paris92, 135–139 (1998).
   PubMedGoogle Scholar
• Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov. Disord8, 479–483 (1993).
   PubMed Web of Science ®Google Scholar
• Matarasso A, Matarasso SL. Botulinum A exotoxin for the management of platysma bands. Plast. Reconstr. Surg.112, 138S–140S (2003).
   Google Scholar
• Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol. Clin.22, 221–226 (2004).
   PubMedGoogle Scholar
• Guyer BM. Some unresolved issues with botulinum toxin. J. Neurol.248(Suppl. 1), 11–13 (2001).
   PubMedGoogle Scholar
• Dressler D. Botulinum Toxin Therapy. Georg Thieme Verlag, Stuttgart, Germany (2000).
   Google Scholar
• Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord.23, 1353–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C, Dolimbek BZ et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology67, 2233–2235 (2006).
   PubMedGoogle Scholar
• Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov. Disord19(Suppl. 8), S53–S59 (2004).
   PubMed Web of Science ®Google Scholar
• Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J. Neurol.252, 904–907 (2005).
   PubMedGoogle Scholar
• Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur. Neurol.48, 26–29 (2002).
   PubMed Web of Science ®Google Scholar
• de Sa Earp AP, Marmur ES. The five D’s of botulinum toxin: doses, dilution, diffusion, duration and dogma. J. Cosmet. Laser Ther.10, 93–102 (2008).
   PubMedGoogle Scholar
• Laurent GJ, Millward DJ. Protein turnover during skeletal muscle hypertrophy. Fed. Proc.39, 42–47 (1980).
   PubMedGoogle Scholar
• Pearson CM. Histopathological features of muscle in the preclinical stages of muscular dystrophy. Brain85, 109–120 (1962).
   PubMed Web of Science ®Google Scholar
• Lebeda FJ, Albuquerque EX. Membrane cable properties of normal and dystrophic chicken muscle fibers. Exp. Neurol.47, 544–557 (1975).
   PubMedGoogle Scholar
• Brin MF. Basic and clinical aspects of BOTOX. Toxicon54, 676–682 (2009).
   PubMedGoogle Scholar
• de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl Acad. Sci. USA96, 3200–3205 (1999).
   PubMed Web of Science ®Google Scholar
• Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J. Physiol.586, 3163–3182 (2008).
   PubMed Web of Science ®Google Scholar
• Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin. Pharmacother.2, 1985–1994 (2001).
   PubMedGoogle Scholar
• Dolly JO, Williams RS, Black JD, Tse CK, Hambleton P, Melling J. Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon20, 141–148 (1982).
   PubMed Web of Science ®Google Scholar
• Amirali A, Sanders I. The glycogen depletion assay and the measurement of botulinum toxin injections In: Scientific and Therapeutic Aspects of Botulinum Toxin. Brin, M, Jankovic, J, Hallett, M (Eds). Lippincott Williams & Wilkins, PA, USA 135–141 (2002).
   Google Scholar
• Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon39, 1309–1315 (2001).
   PubMedGoogle Scholar
• Kalandakanond S, Coffield JA. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther.296, 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci.22, 454–466 (2003).
   PubMed Web of Science ®Google Scholar
• Chushak Y, Foy BD, Frazier JM. Biomolecular Network Simulator. Software for stochastic simulation of cellular biological processes. In: Proceedings of the High Performance Computing Symposium (HPC 2007) Society for Modeling and Simulation International, VA, USA 345–349 (2007).
   Google Scholar
• Chushak Y, Foy B, Fazier J. Stochastic simulations of cellular and biological processes. In: Proceedings of the Users Group Conference. Department of Defense High Performance Computing Modernization Program (DoD HPCMP), PA, USA 425–429 (2007).
   Google Scholar
• Ditlevsen S, de Gaetano A. Stochastic vs. deterministic uptake of dodecanedioic acid by isolated rat livers. Bull. Math. Biol.67, 547–561 (2005).
   PubMedGoogle Scholar
• Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials10, 43 (2009).
   PubMed Web of Science ®Google Scholar
• McConnell P, Dash RC, Chilukuri R et al. The cancer translational research informatics platform. BMC Med. Inform. Decis. Mak.8, 60 (2008).
   PubMedGoogle Scholar
• Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol.5, R80 (2004).
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J. Cosmet. Laser Ther.4, 15–18 (2002).
   PubMedGoogle Scholar
• Sadick NS. Prospective open-label study of botulinum toxin type B (MyoBloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol. Surg.29, 501–507 (2003).
   PubMedGoogle Scholar